56 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
known to have HIV ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
Causes of Thrombocytopenia and Platelet Disorders - Differential Diagnosis and Workup
History:
 - Prior platelet count, family
Risks factor for HIV ... practices that could cause ... decreased PLT count: CBC ... peripheral blood smear, HIV ... (CVID, WAS), (neurologic
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
• In rare cases ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
CNS Infection in HIV / AIDS - Differential Diagnosis Framework

Principles of HIV-Associated CNS Opportunistic Infections:
 •
present in 15% of cases ... status, and focal neurologic ... Demyelinating disease caused ... confusion, and focal neurologic ... InfectiousDiseases #Neurology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Infections in HIV-AIDS ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Infections in HIV-AIDS ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology